Journal of Thrombosis and Thrombolysis

, Volume 47, Issue 1, pp 16–30 | Cite as

A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use

  • Paul GurbelEmail author
  • Udaya Tantry
  • Steven Weisman


The concomitant use of low-dose aspirin for cardioprotection and non-steroidal anti-inflammatory agents for pain relief is prevalent, particularly in the elderly for whom cardiovascular disease and pain are common co-morbidities. Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) are known to interfere with the antiplatelet effect of aspirin through competitive binding with COX-1. While the clinical significance of this interference is still unclear, this review sought to assess the body of literature which has evaluated the potential attenuation of the anti-platelet effect of aspirin when dosed concomitantly with an NSAID. This review supports that the pharmacodynamic interaction between aspirin and non-selective NSAIDs occurs, but finds that the interaction varies amongst agents, and is highly dependent on numerous factors including: dose timing, dose of aspirin, and dose of the NSAID in question. Recent findings suggest that patient factors, such as body weight may also be indicators of aspirin’s cardiovascular effectiveness. Ultimately, the clinical decision making for concomitant NSAID and low-dose aspirin regimens remains at the patient level.


Aspirin Non-steroidal anti-inflammatory drugs Cyclooxygenase-1 Cardiovascular disease 


Compliance with ethical standards


Dr. Gurbel reports receiving grants from the National Institutes of Health, Bayer, Medicure, Instrumentation labs, USWorldMeds, Haemonetics, Amgen, Idorsia, Ionis, Janssen, and Merck; receiving honoraria and payment for lectures, consultations including service on speakers’ bureaus from Bayer, Janssen, Merck, UptoDate, and Medicure; and holding patents in the area of personalized antiplatelet therapy and interventional cardiology. Dr. Tantry reports receiving honoraria from Medicure, AstraZeneca and Upto Date. Dr. Weisman is a consultant to Bayer.


  1. 1.
    Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101:1206–1218CrossRefGoogle Scholar
  2. 2.
    Bibbins-Domingo K, U.S. Preventive Services Task Force (2016) Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 164:836–845CrossRefGoogle Scholar
  3. 3.
    Smith SC Jr et al (2011) AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124:2458–2473CrossRefGoogle Scholar
  4. 4.
    McNeil JJ, Nelson MR, Woods RL, ASPREE Investigator Group et al (2018) Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 379:1519–1528CrossRefGoogle Scholar
  5. 5.
    Zhou Y, Boudreau DM, Freedman AN (2014) Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf 23:43–50CrossRefGoogle Scholar
  6. 6.
    Sopena F, Lanas A (2007) How to advise aspirin use in patients who need NSAIDs. Curr Pharm Des 13:2248–2260CrossRefGoogle Scholar
  7. 7.
    FDA Information for Healthcare Professionals (2006) Concomitant use of ibuprofen and aspirin new information. Accessed 12 Aug 2018
  8. 8.
    Farkouh ME, Greenberg JD, Jeger RV et al (2007) Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66:764–770CrossRefGoogle Scholar
  9. 9.
    Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA (2006) Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98:266–274CrossRefGoogle Scholar
  10. 10.
    Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2013) Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 22:559–570CrossRefGoogle Scholar
  11. 11.
    Yokoyama H, Ito N, Soeda S, Ozaki M, Suzuki Y, Watanabe M, Kashiwakura E, Kawada T, Yamada Y (2013) et al. Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. J Clin Pharm Ther 38:12–15CrossRefGoogle Scholar
  12. 12.
    Patrono C, García Rodríguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373–2383CrossRefGoogle Scholar
  13. 13.
    Catella-Lawson F, Reilly MP et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817CrossRefGoogle Scholar
  14. 14.
    Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, DiGregorio P, Merciaro G, Patrignani P (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45:1295–1301CrossRefGoogle Scholar
  15. 15.
    Gurbel PA, Bliden KP, Zhu J, Troullos E et al (2018) Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. J Thromb Thrombolysis 45:18–26CrossRefGoogle Scholar
  16. 16.
    Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 231:232–235Google Scholar
  17. 17.
    Sellers RS, Radi ZA, Khan NK (2010) Pathophysiology of cyclooxygenases in cardiovascular homeostasis. Vet Pathol 47:601–613CrossRefGoogle Scholar
  18. 18.
    Tantry US, Mahla E, Gurbel PA (2009) Aspirin resistance. Prog Cardiovasc Dis 52:141–152CrossRefGoogle Scholar
  19. 19.
    Kirkby NS, Lundberg MH, Harrington LS et al (2012) Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA 109:17597–17602CrossRefGoogle Scholar
  20. 20.
    Yu Y, Ricciotti E, Scalia R et al (2012) Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 4:132ra154CrossRefGoogle Scholar
  21. 21.
    Majed BH, Khalil RA (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev 64:540–582CrossRefGoogle Scholar
  22. 22.
    Zarraga IG, Schwarz ER (2007) Coxibs and heart disease: what we have learned and what else we need to know. J Am Coll Cardiol 49:1–14CrossRefGoogle Scholar
  23. 23.
    Wallace JL (2008) Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev 88:1547–1565CrossRefGoogle Scholar
  24. 24.
    Ghosh R, Alajbegovic A, Gomes AV (2015) NSAIDs and cardiovascular diseases: role of reactive oxygen species. Oxid Med Cell Longev 2015:536962CrossRefGoogle Scholar
  25. 25.
    Goodman LS, Gilman A (eds) (2011) Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. In: The pharmacological basis of therapeutics, 12th edn. Pergamon Press, New YorkGoogle Scholar
  26. 26.
    Cheema A (2004) Should people on aspirin avoid ibuprofen? A review of the literature. Cardiol Rev 12:174–176CrossRefGoogle Scholar
  27. 27.
    FitzGerald GA, Oates JA, Hawiger J et al (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71:676–688CrossRefGoogle Scholar
  28. 28.
    Patrono C, Ciabattoni G, Patrignani P et al (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72:177–184CrossRefGoogle Scholar
  29. 29.
    Rao GH, Fareed J (2012) Aspirin prophylaxis for the prevention of thrombosis: expectations and limitations. Thrombosis 2012:104707CrossRefGoogle Scholar
  30. 30.
    Patrono C, Ciabattoni G, Pinca E, Pugliese F et al (1980) Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17:317–327CrossRefGoogle Scholar
  31. 31.
    Van Ryn J, Kink-Eiband M, Kuritsch I et al (2004) Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol 44:777–784CrossRefGoogle Scholar
  32. 32.
    Renda G, Tacconelli S, Capone ML, Sacchetta D et al (2006) Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 80:264–274CrossRefGoogle Scholar
  33. 33.
    VanHecken A, Juliano ML, Depre M, Lepeleire ID, Arnout J, Dynder A, Wildonger L, Petty KJ, Gottesdiener K, Hoon JND (2002) Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Aliment Pharmacol Ther 16:1683–1688CrossRefGoogle Scholar
  34. 34.
    Gurbel PA, Bliden KP, DiChiara J, Newcomer J et al (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115:3156–3164CrossRefGoogle Scholar
  35. 35.
    Reilly IA, FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69:180–186Google Scholar
  36. 36.
    Rothwell PM, Cook NF, Gaziano M et al (2018) Effects of aspirin on the risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomized trials. Lancet 392:387–399CrossRefGoogle Scholar
  37. 37.
    Solomon D. NSAIDS (2013) Mechanism of action 2. Accessed on 10 Aug 2018
  38. 38.
    Capone ML, Tacconelli S, Sciulli MG et al (2004) Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109:1468–1471CrossRefGoogle Scholar
  39. 39.
    Cryer B, Berlin RG, Cooper SA et al (2005) Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 27:185–191CrossRefGoogle Scholar
  40. 40.
    Gengo FM, Rubin L, Robson M, Rainka M et al (2008) Effects of ibuprofen on the magnitude and duration of aspirin’s inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 48:117–122CrossRefGoogle Scholar
  41. 41.
    Gladding PA, Webster MWI, Farrell HB et al (2008) The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101:1060–1063CrossRefGoogle Scholar
  42. 42.
    Hong Y, Gengo FM, Rainka MM et al (2008) Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet 47:129–137CrossRefGoogle Scholar
  43. 43.
    Galliard-Grigioni KS, Reinhart WH (2009) A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol 609:96–99CrossRefGoogle Scholar
  44. 44.
    Schiff M, Hochberg MC, Oldenhof J, Brune K (2009) Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 25:2471–2477CrossRefGoogle Scholar
  45. 45.
    Oldenhof J, Hochberg M, Schiff M, Brune K (2010) Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2. Curr Med Res Opin 26:1497–1504CrossRefGoogle Scholar
  46. 46.
    Schuijt MP, Huntjens-Fleuren HW, de Metz M, Vollaard EJ (2009) The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 157:931–934CrossRefGoogle Scholar
  47. 47.
    Angiolillo DJ, Desai B, Hwang C et al (2011) Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane b2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, non-inferiority trial. Clin Ther 33:1883–1893CrossRefGoogle Scholar
  48. 48.
    Anzellotti P, Capone ML, Jeyam A et al (2011) Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 63:850–859CrossRefGoogle Scholar
  49. 49.
    Meek IL, Vonkeman HE, Kasemier J et al (2013) Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69:365–371CrossRefGoogle Scholar
  50. 50.
    Li X, Fries S, Li R, Lawson JA, Propert KJ et al (2014) Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 111:16830–16835CrossRefGoogle Scholar
  51. 51.
    Scheiman JM, Fendrick AM (2007) Summing the risk of NSAID therapy. Lancet 369:1580–1581CrossRefGoogle Scholar
  52. 52.
    Saxena A, Balaramnavar VM, Hohlfeld T, Saxena AK (2013) Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. Eur J Pharmacol 721:215–224CrossRefGoogle Scholar
  53. 53.
    Nalamachu S, Pergolizzi JV, Raffa RB et al (2014) Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf 13:903–917CrossRefGoogle Scholar
  54. 54.
    Fischer LM, Schlienger RG, Matter CM et al (2005) Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 25:503–510CrossRefGoogle Scholar
  55. 55.
    Hudson M, Baron M, Rahme E et al (2005) Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 32:1589–1593Google Scholar
  56. 56.
    Reed GW, Abdallah M, Shao M et al ( 2017) Effect of aspirin on the cardiovascular, gastrointestinal, and renal safety of celecoxib, naproxen, or ibuprofen. American Heart Association 2017 Scientific Sessions, AnaheimGoogle Scholar
  57. 57.
    Feldman M, Cryer B (1999) Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol 84:404–409CrossRefGoogle Scholar
  58. 58.
    Brown N, May JA, Wilcox RG et al (1999) Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br J Clin Pharmacol 48:57–62CrossRefGoogle Scholar
  59. 59.
    Yokoyama H, Yaguchi T, Suzuki Y et al (2012) Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions. Biol Phar Bull 35:2112–2118CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Inova Center for Thrombosis Research and Drug DevelopmentInova Heart and Vascular InstituteFalls ChurchUSA
  2. 2.Platelet and Thrombosis Research, LLCLuthervilleUSA
  3. 3.Innovative Science Solutions, LLCMorristownUSA

Personalised recommendations